Nature Reviews Clinical Oncology, Published online: 09 March 2026; doi:10.1038/s41571-026-01135-0 Glucagon-like peptide 1 receptor agonists (GLP1RAs) are widely used by individuals with type 2 diabetes mellitus (T2DM) and/or obesity. Both of these conditions are also associated with an increased risk of certain cancers, and this risk might be ameliorated following intentional weight loss, which can consistently be achieved with GLP1RAs.
Conversely, several reports have suggested an increased risk of certain cancers, such as medullary or non-medullary thyroid cancer and pancreatic cancer among those receiving GLP1RAs. In this Review, the authors evaluate these competing risks and the underlying evidence as well as highlighting areas in which evidence is limited and more research will be needed in order to definitively understand the implications of GLP1RAs for cancer risk.
Nature Reviews Clinical Oncology published a clinical update in Oncology on 09 Mar 2026.
The item focuses on Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown.
Review the original article for the full source wording and details.